V920
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02314923 | Dec 2014 → Jun 2016 | Ebola hemorrhagic fever | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02296983 | Dec 2014 → Feb 2016 | Ebola hemorrhagic fever | University of Oxford | Unknown | No outcome recorded |
| Phase 1 | NCT02374385 | Nov 2014 → Mar 2015 | Filoviridae infectious disease | Dalhousie University | Completed | No outcome recorded |
| Phase 1 | NCT02283099 | Nov 2014 → Nov 2015 | Ebola hemorrhagic fever | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 1 | NCT02269423 | Oct 2014 → Aug 2015 | Ebola hemorrhagic fever | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02280408 | Oct 2014 → Dec 2015 | Ebola hemorrhagic fever | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02287480 | Nov 2014 → Apr 2015 | Ebola hemorrhagic fever | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02876328 | Mar 2017 → Dec 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02378753 | Apr 2015 → Nov 2016 | Ebola hemorrhagic fever | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02503202 | Aug 2015 → May 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03031912 Comparator | Aug 2017 → Mar 2023 | Ebola hemorrhagic fever | Canadian Immunization Research Network | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V920 | “The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017 |
| Known as | BPSC-1001 | “A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers...” NCT02296983 ↗3“This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (V920; BPSC-1001) to see if it is safe and to see how it affects people's immune system.” NCT02280408 ↗ “To study the anti-Ebola vaccine VSV ZEBOV (BPSC1001) to see if it is safe.” NCT02374385 ↗ |
| Known as | ERVEBO | “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 2022 |
| Known as | rVSV boost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876328 ↗ |
| Known as | rVSV-ZEBOV | “the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees)” PMID 26248510 ↗ Aug 2015 |
| Known as | rVSV-ZEBOV-GP | “V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection” NCT02503202 ↗ |
| Known as | rVSVΔ-ZEBOV-GP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02283099 ↗ |
| Known as | rVSVΔG-ZEBOV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378753 ↗ |
| Known as | rVSVΔG-ZEBOV-GP | “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 20221“The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017 |
| Known as | VSV ZEBOV | “This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (V920; BPSC-1001) to see if it is safe and to see how it affects people's immune system.” NCT02280408 ↗4“This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001.” NCT02269423 ↗ “To study the anti-Ebola vaccine VSV ZEBOV (BPSC1001) to see if it is safe.” NCT02374385 ↗ |
| Known as | VSVΔG-ZEBOV | “This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G...” NCT02314923 ↗3“This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a live VSV replacing the gene encoding the G envelope glycoprotein with the gene...” NCT02280408 ↗ “(VSVΔG-ZEBOV also known as V920 and BPSC-1001).” NCT02269423 ↗ “BPSC-1001 (VSVΔG-ZEBOV)” NCT02374385 ↗ |
| Modality | Vaccine | “This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001.” NCT02269423 ↗ |
| Route | Intramuscular | “Participants will be randomized to receive V920/BPSC-1001 or Placebo by intramuscular injection.” NCT02269423 ↗ |